v3 Template
I

invIOs

Biotechnology / Oncology ~240 employees
Founded
--
Employees (Est.)
~240
12 leaders known
Total Funding
$9.0M
Funding Rounds
1
Last Funding
2024-10-15

About invIOs

invIOs is focused on developing next-generation cancer therapeutics that empower and educate the immune system to fight cancer. They leverage deep expertise in immune-system activation to advance a pipeline of individualized and targeted approaches against solid tumors, aiming to transform patients' lives.

Products & Services

INV501:A high-potential immune-activating small molecule, novel orally available compound, currently in pre-clinical development.
APN401:A tumor-reactive autologous cell therapy with highly-specific and targeted activation of white blood cells, in Phase 1 trials against various solid tumors.
INV441:A tumor-associated cell therapy targeting glioblastoma multiforme with highly specific activation of tumor-infiltrating lymphocytes (TILs), in pre-clinical development.
INV451:Mentioned in the pipeline, but no specific details provided in the content.
Small Molecule Program:A program to discover high-potential compounds for tumor-specific immune activation and tumor cell killing.
Cell Therapy Platform (EPiC):An innovative platform for treating solid tumors, with two disclosed assets.

Specialties

Immune-system activation Cancer therapeutics Small molecule compounds Cell therapy for solid tumors Immuno-oncology

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series A
T: -
FT: Series A 		A: 9020000
MR: -
FA: €8.2 million
FAN: 9020000 		D: 2024-10-15
FD: 2024-10-15 		2 investors
Series A Latest
2024-10-15
$9.0M
2 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

P

Peter Llewellyn-Davies

Chief Executive Officer, Chief Financial Officer

LinkedIn (Pro only)
R

Romana Gugenberger

Chief Medical & Scientific Officer (CMSO)

LinkedIn (Pro only)
G

Gottfried Baier

Professor

LinkedIn (Pro only)
T

Thomas Bogenrieder

Chief Medical Officer

T

Thorsten Füreder

Medical Oncologist

A

Anna Obenauf

Scientific Advisor

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

invIOs Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
invios.com
Industries
Biotechnology / Oncology
Company Size
~240 employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro